Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,750,578
  • Shares Outstanding, K 25,007
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -182,820 K
  • EBIT $ -293 M
  • EBITDA $ -298 M
  • 60-Month Beta 2.95
  • Price/Sales 544.26
  • Price/Cash Flow N/A
  • Price/Book 11.47

Options Overview Details

View History
  • Implied Volatility 82.24% (-45.97%)
  • Historical Volatility 115.65%
  • IV Percentile 15%
  • IV Rank 8.33%
  • IV High 241.91% on 02/07/25
  • IV Low 67.73% on 10/22/25
  • Expected Move (DTE 14) 27.54 (11.11%)
  • Put/Call Vol Ratio 6.04
  • Today's Volume 5,980
  • Volume Avg (30-Day) 1,036
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 18,887
  • Open Int (30-Day) 25,247
  • Expected Range 220.45 to 275.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.00
  • Number of Estimates 8
  • High Estimate -2.17
  • Low Estimate -3.45
  • Prior Year -2.94
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
159.74 +55.25%
on 11/07/25
277.44 -10.61%
on 12/05/25
+83.35 (+50.63%)
since 11/05/25
3-Month
37.19 +566.82%
on 09/08/25
277.44 -10.61%
on 12/05/25
+201.14 (+429.33%)
since 09/05/25
52-Week
26.70 +828.80%
on 04/09/25
277.44 -10.61%
on 12/05/25
+179.86 (+264.00%)
since 12/05/24

Most Recent Stories

More News
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 247.99 (+30.54%)
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 247.99 (+30.54%)
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 Plans to accelerate the development...

PRAX : 247.99 (+30.54%)
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans...

PRAX : 247.99 (+30.54%)
LifeSci Capital Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Praxis Precision Medicines today and set a price target of $373.00. The company’s shares opened today at $158.29.Elevate Your Investing...

PRAX : 247.99 (+30.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 307.18
2nd Resistance Point 292.31
1st Resistance Point 270.15
Last Price 247.99
1st Support Level 233.12
2nd Support Level 218.25
3rd Support Level 196.09

See More

52-Week High 277.44
Last Price 247.99
Fibonacci 61.8% 181.66
Fibonacci 50% 152.07
Fibonacci 38.2% 122.48
52-Week Low 26.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar